Sakar Healthcare Q1 FY27: Higher margins today, an oncology-led export bet for tomorrow

Sakar Healthcare entered FY27 with a strong profitability jump, supported by a richer product mix and a growing contribution from oncology-led exports and technology transfer. In Q1 FY27, consolidated revenue from operations rose to ₹7,297 lakhs (₹72.97 crore), up 38% year on year. EBITDA increased faster, up 67% to ₹2,125 lakhs (₹21.25 crore), taking EBITDA margin to 29%. PAT more than doubled to ₹1,028 lakhs (₹10.28 crore), with PAT margin at 14%.

Management framed the quarter as a continuation of the company’s transition from a contract manufacturing-led model to a more integrated, regulatory-driven oncology platform. The core idea is straightforward: expand the oncology portfolio, build regulatory market access through dossiers and filings, and scale up exports and partner-led launches as approvals convert into commercial orders.

A quarter where operating leverage showed up in the P&L

The profit and loss statement shows that Sakar’s gross profit expanded sharply, reflecting better mix and operating leverage. Gross profit rose to ₹3,839 lakhs (₹38.39 crore) in Q1 FY27, versus ₹2,378 lakhs (₹23.78 crore) in Q1 FY26. Gross margin improved to 53% from 45%.

Employee and other expenses increased as well, but the pace of operating profit growth remained higher than revenue growth. Depreciation stayed elevated at ₹654 lakhs (₹6.54 crore), and finance cost was ₹167 lakhs (₹1.67 crore). The company reported profit before tax of ₹1,458 lakhs (₹14.58 crore) and profit after tax of ₹1,028 lakhs (₹10.28 crore).

The numbers are important, but management’s commentary suggested the deeper story is the oncology ramp. In the concall, the company disclosed that oncology revenue in Q1 FY27 was around ₹33 crore, of which exports were about ₹6.5 crore and the balance was domestic.

Oncology as the growth engine: filings, approvals, and tech transfers

In the investor presentation, oncology was positioned as the company’s “driving growth engine”, anchored by an EU-GMP approved Bavla facility with integrated API and finished dosage manufacturing capabilities. The company highlighted progress across contracts, dossiers, filings, and technology transfer.

Key operational disclosures for Q1 FY27 included more than 65 oncology product contracts executed, with 50+ commercial discussions underway. The company stated it shared 261 dossiers globally, with 178 submitted and 16 marketing authorisations received.

On Europe specifically, the company disclosed 26 EU marketing authorisation filings in the quarter, including 15 owned filings. It also stated that 6 additional marketing authorisations were procured through partners in Bulgaria and Bosnia, while other markets mentioned as filed included Czech Republic, Croatia and Poland.

Technology transfer has become a central part of the oncology business model. Management disclosed 33 ongoing oncology technology transfer projects with partners including Accord-Intas, Torrent (UK and Germany), Emcure, Glenmark and Zydus. Seven projects have received site variation approvals across the UK and EU.

In the Q&A, management gave product-level color around the tech transfer approvals. It stated five approvals were for Accord and included Imatinib, Azacitidine, Exemestane, Sorafenib (oral solids) and Cytarabine injection. It also stated three products have already been commercialised with dispatches made, and that Torrent’s German partner (Heumann) has received supplies linked to a tender with Letrozole.

This matters because tech transfers and site variations tend to create stickier, longer-duration partner relationships. Management repeatedly positioned these projects as a shift from transactional supply to strategic manufacturing partnerships.

The integration lever: in-house oncology APIs and CEP progress

A key part of the company’s differentiation is backward integration into oncology APIs. In the presentation, Sakar disclosed 21 APIs developed in-house, with 16 supported by Written Confirmation. It also disclosed 2 APIs with CEP approval and 5 CEP applications in process.

In the concall, management named the two CEP-approved APIs as Gefitinib and Cytarabine, and explicitly said the objective is to use these APIs for backward integration into Sakar’s own finished dosage pipeline, rather than primarily selling them to the external market.

On margins, management indicated the non-oncology business has historically been around 25% EBITDA margin, while oncology has the potential to move towards 30% and, with deeper API integration, around 35% or even higher.

What management guided, and what the market will watch

Management’s forward-looking statements were clear on ambition, but also included the usual constraint of regulatory timelines. It stated that approval timelines are not directly within the company’s control and that approvals can take roughly 12 months on average.

Still, management provided several directional guideposts:

First, it stated that export contribution from oncology should start picking up from Q3 FY27 onwards as marketing authorisation alignment and supplies scale up.

Second, it indicated a plan to double oncology revenue in FY27 versus FY26 (management referenced oncology contribution of around ₹93 to ₹94 crore in the last financial year). It also stated that by end of FY27 it expects exports to be about 30% of the oncology mix, with domestic and other components forming the balance.

Third, for FY28, management indicated oncology revenue could be around three times the FY26 level, and agreed with an investor estimate of around ₹280 to ₹300 crore.

Finally, the company reiterated a longer-term platform claim: the Bavla oncology facility can support ₹800 crore to ₹1,000 crore of revenue at optimal utilisation over 4 to 5 years without requiring major incremental capex.

The execution checkpoints for investors are therefore practical and measurable. These include whether the 178 submitted dossiers convert into more approvals, whether marketing authorisation-based launches scale beyond initial dispatches, whether tech transfer partners translate approvals into sustained orders, and whether export mix increases in line with management’s own commentary.

Sakar’s Q1 FY27 shows a company enjoying operating leverage today while spending effort on a regulatory and partnership-driven oncology export buildout. If approvals and launches track expectations, the earnings profile can continue to shift toward higher-margin oncology revenues. If timelines slip, near-term growth may remain more dependent on the existing domestic and CDMO base. Either way, the next few quarters are set up as a validation phase for the export ramp that management expects from Q3 onwards.